IART - Integra LifeSciences Holdings Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
46.80
+0.44 (+0.95%)
As of 12:31PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close46.36
Open46.55
Bid46.79 x 1400
Ask46.81 x 800
Day's Range46.00 - 47.37
52 Week Range42.14 - 67.50
Volume158,596
Avg. Volume604,803
Market Cap3.986B
Beta (3Y Monthly)1.31
PE Ratio (TTM)48.05
EPS (TTM)0.97
Earnings DateFeb 25, 2019 - Mar 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est58.07
Trade prices are not sourced from all markets
  • Markit3 days ago

    See what the IHS Markit Score report has to say about Integra LifeSciences Holdings Corp.

    # Integra LifeSciences Holdings Corp ### NASDAQ/NGS:IART View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for IART with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $5.90 billion over the last one-month into ETFs that hold IART are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Integra LifeSciences Unveils Titan RSS-S, Widens Portfolio
    Zacks7 days ago

    Integra LifeSciences Unveils Titan RSS-S, Widens Portfolio

    The latest launch reflects Integra LifeSciences' (IART) consistent efforts to boost the Orthopedics and Tissue Technologies segment.

  • GlobeNewswire8 days ago

    Recent Analysis Shows T-Mobile US, Thor Industries, Integra LifeSciences, Diplomat Pharmacy, Tile Shop Hldgs, and Compass Diversified Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Jan. 10, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire8 days ago

    Integra LifeSciences Launches Integra® Titan™ Reverse Shoulder System-S

    PLAINSBORO, N.J., Jan. 10, 2019 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced the full market release.

  • Integra (IART) Rises 5% on Robust Preliminary Q4 Results
    Zacks9 days ago

    Integra (IART) Rises 5% on Robust Preliminary Q4 Results

    Integra's (IART) total Q4 revenues are likely to be at the upper end of its prior guided range.

  • Should We Worry About Integra LifeSciences Holdings Corporation’s (NASDAQ:IART) P/E Ratio?
    Simply Wall St.9 days ago

    Should We Worry About Integra LifeSciences Holdings Corporation’s (NASDAQ:IART) P/E Ratio?

    This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). We'll show how you can use Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Read More...

  • Markit9 days ago

    See what the IHS Markit Score report has to say about Integra LifeSciences Holdings Corp.

    # Integra LifeSciences Holdings Corp ### NASDAQ/NGS:IART View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for IART with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding IART is favorable, with net inflows of $11.37 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire9 days ago

    Integra LifeSciences Appoints Rhonda Germany Ballintyn as Director

    PLAINSBORO, N.J., Jan. 09, 2019 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced the appointment of.

  • GlobeNewswire10 days ago

    Integra LifeSciences Announces Agreement with Consortium of Focused Orthopedists to Develop a Short Stem and Stemless Shoulder System

    Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced it has signed a license and development agreement with Consortium of Focused Orthopedists, LLC (CFO), for a short stem and stemless shoulder system.  This is a key addition to Integra’s Extremity Orthopedics portfolio in a fast-growing segment of the shoulder arthroplasty market and is expected to accelerate growth opportunities globally. “We designed this system to allow for patients to be anatomically suited to experience the bone-sparing benefits of a short stem,” said Dr. Armodios Hatzidakis, Orthopaedic Surgeon, Western Orthopaedics, and one of the design surgeons with CFO. “We are excited to partner with these leading shoulder surgeons from CFO­­­ on this technology,” said Robert T. Davis, Jr., corporate vice president and president, Orthopedics and Tissue Technologies.  “With the addition of a short stem and stemless shoulder system, we will have a competitive design in a large and fast-growing segment of shoulder arthroplasty.

  • GlobeNewswire10 days ago

    Integra LifeSciences Announces Preliminary Fourth Quarter 2018 Financial Results

    Preliminary Fourth Quarter 2018 Highlights: Fourth quarter 2018 reported revenue is expected to be at the higher end of the company’s previous guidance range of $378 million to.

  • Integra Rides on Global Prospects, Hurt by Escalating Costs
    Zacks25 days ago

    Integra Rides on Global Prospects, Hurt by Escalating Costs

    Integra LifeSciences (IART) aims at investment openings in the Asian market for a faster business boost than in the United States and also to flourish specific parts of its international businesses.

  • Do Hedge Funds Love Integra Lifesciences Holdings Corp (IART)?
    Insider Monkey27 days ago

    Do Hedge Funds Love Integra Lifesciences Holdings Corp (IART)?

    Out of thousands of stocks that are currently traded on the market, it is difficult to determine those that can really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

  • How Does Medtronic’s Restorative Therapies & Diabetes Group Look?
    Market Realistlast month

    How Does Medtronic’s Restorative Therapies & Diabetes Group Look?

    Medtronic’s Restorative Therapies Group consists of Spine, Brain, Specialty, and Pain therapies. Medtronic’s Restorative Therapies Group generated revenues of $2.0 billion in the second quarter of fiscal 2019 compared to $1.9 billion in the second quarter of fiscal 2018, reflecting ~7% YoY growth.

  • Integra (IART) Down 2.2% Since Last Earnings Report: Can It Rebound?
    Zacks2 months ago

    Integra (IART) Down 2.2% Since Last Earnings Report: Can It Rebound?

    Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Integra's (IART) Margin Pressure Hurts, Global Prospects High
    Zacks2 months ago

    Integra's (IART) Margin Pressure Hurts, Global Prospects High

    Massive gross margin declines induced by mounting costs are a major downside for Integra LifeSciences (IART).

  • GlobeNewswire2 months ago

    Integra® XT Revision Total Ankle Replacement System Offers Innovative Solution to Ankle Arthroplasty Revision Surgery

    PLAINSBORO, N.J., Nov. 20, 2018 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced one of the first.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of IART earnings conference call or presentation 31-Oct-18 12:30pm GMT

    Q3 2018 Integra Lifesciences Holdings Corp Earnings Call

  • GlobeNewswire2 months ago

    Integra LifeSciences Appoints Eric Schwartz, Corporate Vice President, General Counsel and Secretary

    PLAINSBORO, N.J., Nov. 12, 2018 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment of Eric Schwartz as corporate vice president, general.

  • See what the IHS Markit Score report has to say about Integra Lifesciences Holdings Corp.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Integra Lifesciences Holdings Corp.

    Integra Lifesciences Holdings Corp NASDAQ/NGS:IART

  • GlobeNewswire2 months ago

    Integra LifeSciences to participate in Healthcare Conferences in November 2018

    PLAINSBORO, N.J., Nov. 08, 2018 -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following.

  • GlobeNewswire2 months ago

    Detailed Research: Economic Perspectives on Integra LifeSciences, American Assets Trust, Teekay Offshore Partners, Acacia Communications, Piedmont Office Realty Trust, and Macerich — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 07, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Integra (IART) Q3 Earnings Meet Estimates, Revenue View Dips
    Zacks3 months ago

    Integra (IART) Q3 Earnings Meet Estimates, Revenue View Dips

    Integra LifeSciences' (IART) success with its channel expansion policy and Codman acquisition raise optimism on the stock.

  • Integra LifeSciences (IART) Matches Q3 Earnings Estimates
    Zacks3 months ago

    Integra LifeSciences (IART) Matches Q3 Earnings Estimates

    Integra (IART) delivered earnings and revenue surprises of 0.00% and -1.28%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?